Chemoprevention and chemotherapy by inhibition of ornithine decarboxylase activity and polyamine synthesis: colonic, pancreatic, mammary, and renal carcinomas.
Specific, irreversible, inhibition of ODC activity with DFMO and resultant low levels of intracellular polyamines markedly suppress the induction of experimental colonic and mammary cancers and hold promise for augmenting the multidrug chemotherapy of established colonic, pancreatic, renal and mammary cancers without increasing systemic toxicity.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism*; D002455:Cell Division; D003110:Colonic Neoplasms / Q000378:metabolism*; D000518:Eflornithine; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism*; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism; D051379:Mice; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D065108:Ornithine Decarboxylase Inhibitors; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D011073:Polyamines / Q000096:biosynthesis*; D051381:Rats
D000970:Antineoplastic Agents; D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines; D009952:Ornithine; D000518:Eflornithine